RxDoctor Payments Data

Charlie Faulk, MD

Gynecology · Newport News, VANPI 1336225689

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.1% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations.

$2,702in general payments, 2019–2025

Across 147 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$606
  • Shield Therapeutics Inc$279
  • AbbVie$273
  • Pfizer$266
  • Organon$175
  • Sumitomo Pharma America, Inc.$163
  • plus $939 from 18 others

What the payments were for

  • Food & beverage$2,49092%
  • Education$2128%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,702 in reported general payments places this provider in the 85th percentile of 71 gynecology providers in Virginia.

See all gynecology providers in Virginia

Medicare billing

Part B allowed, 2024
$37,452
Medicare patients
154
Services billed
703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron21$15,852
Estradiol146$9,575
YuvafemEstradiol12$1,675
Tolterodine Tartrate ErTolterodine Tartrate14$1,625
Solifenacin Succinate37$1,149
Oxybutynin Chloride ErOxybutynin Chloride75$1,141
Clobetasol Propionate26$1,078
Estradiol (Once Weekly)Estradiol16$1,008
ValacyclovirValacyclovir Hcl24$925
ProgesteroneProgesterone, Micronized25$880
Raloxifene Hcl29$732
Gabapentin40$642
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip42$630
Estradiol (Twice Weekly)Estradiol12$516
Metronidazole16$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$606$15,85221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 71 gynecology providers in Virginia.

Other gynecology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →